Description
Buy Danyelza (naxitamab-gqgk) Online
Danyelza (Naxitamab-gqgk) Injection is a GD2-binding monoclonal antibody used, along with granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have shown a partial response, minor response, or stable disease to prior therapy.
Dosage: The recommended dosage of naxitamab-gqgk is 3 mg/kg daily (up to 150 mg daily) on Days 1, 3, and 5 of each treatment cycle, administered as an intravenous infusion after dilution in combination with GM-CSF subcutaneously. Treatment cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks. Subsequent cycles may be repeated every 8 weeks. Discontinue your naxitamab-gqgk dosage and GM-CSF for disease progression or unacceptable toxicity.
Side Effects: The most commonly reported danyelza injection side effects (≥25%) include:
- Pain
- Tachycardia
- Vomiting
- Cough
- Nausea
- Diarrhea
- Decreased appetite
- Hypertension
- Fatigue
- Urticaria
- Pyrexia
- Headache
- Injection site reaction
- Edema
- Anxiety
- Localized edema
- Irritability
- Erythema multiforme
- Peripheral neuropathy
- Infusion-related reaction
Warnings and Precautions:
- The danyelza injection uses is restricted in patients with a history of severe hypersensitivity reaction to it.
- Monitor patients for signs/symptoms of infusion reactions during and for at least 2 hours following completion of each naxitamab-gqgk infusion.
- Monito+9r patients for blood pressure during infusion, and at least daily on Days 1-8 of each cycle of danyelza injection and assess for complications of hypertension including RPLS.
- The mechanism of action of danyelza suggest that it may cause fetal harm if administered to a pregnant woman.
- Women should avoid breastfeeding during treatment with naxitamab-gqgk and for two months following the final dose.
